Cas:113963-68-1 n-methylbis(indol-3-yl)maleimide manufacturer & supplier

Chemical Name:n-methylbis(indol-3-yl)maleimide

CAS.NO:113963-68-1

Synonyms:Ro 31-6045;2,3-bis(1H-Indol-3-yl)-N-methylmaleimide;MFCD00236433;3,4-Di(1H-indol-3-yl)-1-methyl-1H-pyrrole-2,5-dione;bisindolylmaleimide v;3,4-bis(3-indolyl)-1-methyl-pyrrole-2,5-dione;1-Methyl-3,4-bis(3-indolyl)maleimide;1H-Pyrrole-2,5-dione,3,4-di-1H-indol-3-yl-1-methyl;1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-1-methyl-;n-methylbis(indol-3-yl)maleimide

Molecular Formula:C₂₁H₁₅N₃O₂

Molecular Weight:341.363

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:655.7±55.0 °C at 760 mmHg

Density:1.5±0.1 g/cm3

Index of Refraction:1.794

PSA:68.96000

Exact Mass:341.116425

LogP:3.65

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Ro 31-6045 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,n-methylbis(indol-3-yl)maleimide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00236433 Use and application,1-Methyl-3,4-bis(3-indolyl)maleimide technical grade,usp/ep/jp grade.

Related News: The workers are demanding that Hong Kong close all border checkpoints to visitors from mainland China, saying they represent a threat to health care workers in the city. n-methylbis(indol-3-yl)maleimide manufacturer The workers are demanding that Hong Kong close all border checkpoints to visitors from mainland China, saying they represent a threat to health care workers in the city. n-methylbis(indol-3-yl)maleimide supplier FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus. n-methylbis(indol-3-yl)maleimide vendor Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. n-methylbis(indol-3-yl)maleimide factory The researchers found that compared with those with cancer, the prevalence of FT was higher among those with ASCVD (54 versus 41 percent). In adjusted analyses, when studying individual components of FT, those with ASCVD had increased odds of any difficulty paying medical bills, inability to pay bills, cost-related medication nonadherence, food insecurity, and foregone/delayed care due to cost (odds ratios, 1.22, 1.25, 1.28, 1.39, and 1.17, respectively).